Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated (PRLD) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · PRLD · as of Jun 9, 2026
Key Statistics
Explore Prelude Therapeutics Incorporated Data
prld stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 8 · Buy rate: 62.5%
The PRLD analyst consensus is Buy, based on ratings from 8 Wall Street analysts over the past 3 months. The average 12-month price target is $8.00, representing +100.50% upside from the current price of $3.99.
Competitors & Peers
prld competitorsPRLD
AVTX
CRBU
ENTA
EPRX
FHTXStock Performance
Full HistoryAbout Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs.…
what is prelude therapeutics incorporated · prld stock overview · prelude therapeutics incorporated company profile · who is prelude therapeutics incorporated ceo · prld NASDAQ · prelude therapeutics incorporated headquarters · prelude therapeutics incorporated business segments
About Stock Overview & Key Data
Prelude Therapeutics Incorporated (PRLD) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Sep 25, 2020. As of the latest trading session, PRLD stock price is $3.99, with a market capitalization of $227.2M. The stock has returned +225.42% over the past 12 months and +32.41% year-to-date.
According to 8 Wall Street analysts, the consensus rating for Prelude Therapeutics Incorporated stock is Buy, with an average 12-month price target of $8.00. In fiscal year 2025, Prelude Therapeutics Incorporated reported revenue of $12.1M and net income of -$99.5M. For detailed data — including Prelude Therapeutics Incorporated revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Prelude Therapeutics Incorporated (PRLD) stock price is $3.99. The stock is traded on NASDAQ under the ticker symbol PRLD. The 52-week range is $0.75 – $5.54.